Welcome to the 2nd Precision Medicine in Inflammatory Bowel Disease Summit!
Curated in collaboration with key thought-leaders, the 2nd Precision Medicine in Inflammatory Bowel Disease Summit was designed as the only industry-dedicated forum solely focused on understanding and overcoming hurdles with tailored-treatment, exploring novel therapeutic avenues and the latest developments in biomarker discovery, to get safer, more efficacious drugs into the clinic.
Leading experts were assembled to present the most innovative data, while senior decision-makers guided discussions around pivotal breakthroughs and strategic approaches.
Attendees joined us in March for an immersive experience, featuring in-depth and valuable conversations aimed at accelerating the progress of precision medicine in IBD research and development.
Conference Highlights Included:
Uncovering how AI and machine learning can provide unique insights into IBD heterogeneity, patient prognosis, and drug development with Merck, Takeda and Alumis
Maximizing the effectiveness of available drugs by wielding the power of synergy with Janssen and Palatin Technologies
Leveraging key learnings from developing prognosis biomarkers to understand IBD heterogeneity with Harvard Medical School and Galapagos
Unlocking insights into effective patient stratification to optimize drug response rate and improve clinical outcomes, with Takeda, Crohn’s & Colitis Foundation, and Seres Therapeutics
Exploring the hottest developments in disease monitoring and management with Mount Sinai, Bristol Myers Squibb, and Pfizer